This was the first study to assess the prevalence of MBS in Lebanese subjects with psoriasis and, to our knowledge, the first study that showed a higher likelihood of MBS in patients with inverse psoriasis and with nail pitting.
The aim of this study is to assess the nutrition situation in terms of knowledge, attitude and practices (KAP) among recently delivered Syrian refugee women and to identify nutrition related KAP problems of this vulnerable population. An analytical descriptive cross-sectional study was conducted on a nonrandomized sample of one hundred recently delivered Syrian women from refugee background aged 18 years old and above who were admitted for delivery to the obstetric unit of a governmental hospital located in Beirut, Lebanon. The study reveals that fifty-six percent of the studied population was not knowledgeable about maternal nutrition during pregnancy, twenty-five percent had a negative attitude toward antenatal care (ANC) services and nutrition during pregnancy and forty-seven percent of the participants were having bad dietary practices during pregnancy. Knowledge, attitude and practices toward nutrition and diet during pregnancy are still lacking among this sensitive population.
Biologists have been extensively investigating a promising therapy in the management of multiple inflammatory and autoimmune diseases. Rituximab is a chimeric (murine/human) monoclonal antibody, which targets a cluster of 20 different antigens (CD20) found on the surface of B-lymphocytes.Rituximab is approved by the Food and Drug Administration (FDA) for the treatment of rheumatoid arthritis, non-Hodgkin's lymphoma 1 and recently of anti-neutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV).2 In addition to these indications, rituximab is being used as an off-label treatment in a number of inflammatory and systemic autoimmune diseases. Off-label use dictates the prescription of a registered medicine for a use that is not included in the product information. It is considered appropriate when there is high-quality evidence, or where the use is within the context of a formal research proposal, or in exceptional cases, justified by clinical situations.3 Rituximab has been tried as an off-label treatment for many conditions including systemic lupus erythematosus (SLE), Sjögren's syndrome, idiopathic thrombocytopenic purpura (ITP), systemic vasculitides, bullous dermatologicObjectives: This study aims to evaluate the efficacy of off-label use of rituximab with possible side effects. Patients and methods: Records of the 44 American University of Beirut Medical Center pharmacies were searched for patients who used rituximab over the past 4.5 years, and data on rituximab dosage, protocol and side effects were documented. The majority of patients had systemic lupus erythematosus. Autoimmune thrombocytopenic purpura, antiphospholipid syndrome, Sjögren's syndrome, Wegener's granulomatosis, autoimmune hemolytic anemia, dermatomyositis, and pemphigus vulgaris were also reported. Outcome measures were improvement in signs and symptoms during a follow-up period of two years. Results: Twenty-nine out of the 44 patients had complete response without relapse. Of those, 12 patients were in remission after the first cycle. Of the systemic lupus erythematosus cases, 12 had complete response without relapse; of which, five patients had remission after the first cycle. No significant toxicities were noted.
Conclusion:The off-label use of rituximab in various inflammatory diseases showed improvement in symptoms with no significant side effects in patients who have failed previous treatment with multiple conventional regimens.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.